NCT01505439已完成4 期
A Prospective, Open Label, Single Arm, Multicenter Study to Estimate the Efficacy and Safety of Solifenacin in Female With Clinically Significant Stress Urinary Incontinence and Urgency Urinary Incontinence
Jeong Gu Lee6 个研究点 分布在 1 个国家目标入组 311 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 311
- 试验地点
- 6
- 主要终点
- Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12
研究概览
简要总结
This study is to investigate the effects of solifenacin on urgency urinary incontinence symptoms and incontinence quality-of-life (I-QoL) in female patients with clinically significant stress urinary incontinence accompanied by urgency urinary incontinence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients are selected from those who meets one of criteria
- •Patients with a positive cough provocation test
- •Based on 3-day voiding diary, patients with:
- •Urinary frequency (eight or more micturitions per day or 24 hours)
- •Urinary urgency (two or more episodes per day or 24 hours)
- •Urge incontinence (three or more episodes for 3 days)
排除标准
- •Breast-feeding women or females of childbearing potential with the intention to become pregnant during the study
- •Post-void residual urine volume (PRV) of 150 cc or more
- •Patients who experienced acute ureteral obstruction requiring an indwelling catheter
- •Patients who experienced clinically significant pelvic organ prolapse or lower urinary tract surgery within 6 months prior to the initiation of the present study
- •Patients who underwent a urinary incontinence operation within 1 year
- •Any condition that, in the opinion of the investigator, is a contraindication for anticholinergic treatment, including severe narrow-angled glaucoma, urinary retention, gastric retention, severe myasthenia, severe hepatic insufficiency or severe ulcerative colitis
- •Significant hepatic or renal disease, defined as having greater than twice the upper limit of the reference ranges for serum concentrations of aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase or creatinine
- •Patients who have any of neurological disorders such as stroke, multiple sclerosis, spinal cord injury, and Parkinson's disease
- •Patients who use an indwelling catheter or practice intermittent self-catheterization
- •Recurrent UTIs defined as having been treated for symptomatic UTIs 3 times or more in the last year
- •Symptomatic acute urinary tract infection (UTI) during the run-in period
- •Patients who received any of the following prohibited concomitant drugs within 14 days prior to randomization: Treatment performed within the 14 days preceding randomization, or expected to initiate treatment during the study with:
- •Any anticholinergics other than the trial drug
- •Any drug treatment for overactive bladder. Estrogen treatment started more than 2 months prior to inclusion is allowed
- •Patients taking an unstable dosage of any drug with anticholinergic side effects, or expected to start such treatment during the study
- •Patients with chronic constipation or history of severe constipation
- •Treatment with any of potent CYP3A4 inhibitors, such as cyclosporine, vinblastine, macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin) or antifungal agents (e.g. ketoconazole, itraconazole, micronazole)
- •Sexually active females of childbearing potential not using reliable contraception for at least 1 month prior to study initiation and not agreeing to use such methods during the entire study period and for at least 1 month thereafter. Reliable contraceptive methods are defined as intrauterine devices (IUDs), combination type contraceptive pills, hormonal implants, double barrier method, injectable contraceptives, surgical procedures (tubal ligation or vasectomy), or continence
- •Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
研究组 & 干预措施
Solifenacin group
Experimental
Once daily
干预措施: solifenacin (Drug)
结局指标
主要结局
Changes in the number of urge urinary incontinence episodes per 24 hours between baseline and week 12
时间窗: Baseline and week 12
次要结局
- Percent change in the mean number of urge urinary incontinence episodes per 24 hours(Baseline, week 4 and week 12)
- Change in the mean number of urge urinary incontinence episodes per 24 hours(Baseline, week 4 and week 12)
- Change in the mean frequency of urination per 24 hours(Baseline, week 4 and week 12)
- Percent change in the mean frequency of urination(Baseline, week 4 and week 12)
- Changes in the mean and sum rating on the Bladder Sensation Scale per 24 hours(Baseline, week 4 and week 12)
- Change in the mean number of severe urgency episodes per 24 hours(Baseline, week 4 and week 12)
- Changes in overactive bladder symptom score (OABSS) questionnaire(Baseline, week 4 and week 12)
- Changes in short urogenital distress inventory (UDI-6)(Baseline, week 4 and week 12)
- Changes in short incontinence impact questionnaire (IIQ-7)(Baseline, week 4 and week 12)
- Safety assessed by the incidence and severity of side effects(For 12 weeks)
研究者
Jeong Gu Lee
Professor
Korea University Anam Hospital
研究点 (6)
Loading locations...
相似试验
Unknown
2 期
Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURPOveractive Bladder SyndromeNCT03632772Buddhist Tzu Chi General Hospital130
Unknown
不适用
The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual FunctionUrge IncontinenceUrgency-frequency SyndromeNCT05391425Istanbul University150
已完成
3 期
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder SymptomsUrinary Bladder, OveractiveNCT00463541Astellas Pharma Inc2,225
已完成
4 期
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.Detrusor OveractivityOveractive BladderNCT01093534Astellas Pharma Inc547
已完成
4 期
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseOveractive Bladder in Parkinson's DiseaseNCT01018264University of South Florida23